Anthropic Success


Anthropic designed 1,320 miniproteins for 15 targets, and two laboratories verified their binding on August 18. Anthropic published the campaign results, a full technical report, and open data. Out of 1,320 sequences, 354 were recognized as binding by the combined assessment of two contract laboratories.

The miniprotein in this campaign was required to attach to a selected protein target. To achieve this, a site on the surface of the target needed to be chosen, and the shape and amino acid sequence of the candidate had to be selected, manufactured, and measured for binding. Anthropic selected the targets and prepared a general protocol. Claude studied each target, chose a site on its surface, launched open programs to build the shape and select amino acids, checked candidates on a computer, and selected the final lists for the laboratory.

In Nature Aging, July 2026, similar research was conducted. The current campaign involved a longer chain: the agent itself chose what and how to design, and the laboratory measured each final candidate on a series of targets. In May, Adaptyv Bio tested 100 protein candidates created by ten human teams and six AI agents for TREM2, a protein on immune cells in the brain. In the current campaign, this laboratory participated in verifying 15 targets, and Anthropic revealed the results for each transmitted sequence. Anthropic passed the final sequences to two contract laboratories - Adaptyv Bio and Twist Bioscience.

🔗 Read original →

Aging Cells Impact Therapy


The journal Frontiers in Aging published a review on August 17, 2026, about mesenchymal stromal cells (MSC) and their use in tissue repair and inflammation management. The authors explain that basic quality control may not be enough, as the product may appear viable but perform worse in specific therapies. The review outlines the path of the cell product from donor to patient, including growth, freezing, transportation, and thawing, where cells may experience stress at each stage.

Cell aging is a persistent state where cells divide less often, change their metabolism, and alter the signals they send to surrounding tissue, leading to a decrease in the product's ability to perform its intended function. The authors note that the product may retain acceptable viability and surface markers but have already lost important functionality. The review links stress to loss of function through a chain of events, including DNA damage and mitochondrial dysfunction.

The source of the cells determines where this chain begins, with bone marrow-derived MSC being affected by donor age and inflammation in the bone marrow. Cells from umbilical cord tissue are typically younger but are affected by growth, freezing, thawing, and transportation. For adipose tissue-derived MSC, donor obesity, diabetes, and metabolic inflammation are important factors. The authors suggest linking testing to the product's intended use, such as checking if cells can suppress T-cell activation for inflammation or observing vascular cell migration for tissue repair.

🔗 Read original →

NeuroQuant PET Approved


The FDA has approved NeuroQuant PET, a program that translates amyloid PET scans into a common scale. On August 12, the FDA granted a "Substantially Equivalent" decision for NeuroQuant PET under the K261916 application. The program automatically generates a quantitative report for amyloid PET scans in patients with cognitive impairments and other neurological conditions.


The amyloid PET scan shows where a tracer accumulates in the brain, binding to amyloid deposits. However, the resulting number depends on the tracer, scan time, device, and calculation method, making it difficult to compare results from different studies and clinics. The Centiloid scale translates these results into common units, with zero corresponding to the average value in young individuals with high confidence in the absence of amyloid, and 100 corresponding to the average value in typical Alzheimer's disease patients.


NeuroQuant PET performs this translation for a given scan, highlighting brain regions, calculating SUVr, and adding the Centiloid value to a structured report. According to Cortechs.ai, the FDA approval applies to amyloid reports for flutemetamol, florbetaben, and florbetapir. The scale, created for research comparison, becomes part of the automatic clinical report, supplementing the image with a number that is equally readable across different tracers and analysis methods.

🔗 Read original →

NeuroQuant PET Approved


The FDA has approved NeuroQuant PET, a program that translates amyloid PET scans into a common scale. On August 12, the FDA granted a "Substantially Equivalent" decision for NeuroQuant PET under the K261916 application. The program automatically generates a quantitative report for amyloid PET scans in patients with cognitive impairments and other neurological conditions.


The amyloid PET scan shows where a tracer accumulates in the brain, binding to amyloid deposits. However, the resulting number depends on the tracer, scan time, device, and calculation method, making it difficult to compare results from different studies and clinics. The Centiloid scale translates these results into common units, with 0 corresponding to the average value in young individuals with high confidence in the absence of amyloid, and 100 corresponding to the average value in typical Alzheimer's disease patients.


NeuroQuant PET performs this translation for a given scan, highlighting brain regions, calculating SUVr, and adding the Centiloid value to a structured report. According to Cortechs.ai, the FDA approval extends to amyloid reports for flutemetamol, florbetaben, and florbetapir. The scale, created for research comparison, becomes part of the automatic clinical report, supplementing the image with a number that is equally readable across different tracers and analysis methods.

🔗 Read original →

Brain Atlas Study


A recent study published in Cell on August 18 has created a detailed map of the brain of 23 female macaques, highlighting the white matter of the brain stem as particularly vulnerable to age-related changes. The researchers collected 2,955,873 cell nuclei and tracked how age-related shifts are distributed across different brain regions and cell types.



The study found that the brain ages unevenly in different regions and cells, with the most consistent age-related shifts found in the pons and medulla - regions of the brain stem. The white matter in these regions consists of bundles of nerve fibers coated with myelin, a fatty substance that accelerates signal transmission. The researchers observed a decline in the activity of genes related to myelin and lipid synthesis in oligodendrocytes, the cells responsible for producing myelin.



The study's findings also showed changes in the signals of cells that support nerve tissue or give rise to oligodendrocytes. The researchers confirmed a decrease in PDGFRA gene RNA in oligodendrocyte precursor cells, which codes for a receptor of growth signals. The study's data is available on the NHPABC portal, allowing researchers to search for age-related shifts by specific brain region, cell type, and programs related to myelin.

🔗 Read original →

Virtual Cell Technology


GenBio AI has introduced a digital cell system, AIDO Cell, which allows biologists to experiment on a computer. AIDO Cell is a "virtual cell" that belongs to a new generation of AI models attempting to model entire biological systems, rather than just predicting individual properties. The main difference from systems like AlphaFold is the scale, as AlphaFold can predict protein structure from amino acid sequences, but a protein is just one element of a cell.


AIDO attempts to link multiple levels of biology: DNA → RNA → proteins → cellular processes → overall cell behavior. The ability to conduct virtual experiments is particularly interesting, as researchers can set up an experiment, such as changing the activity of a specific gene or adding a drug, and the model attempts to predict the consequences at different levels of biology.


The system retains the state of the system between experiments, allowing for more complex and realistic simulations. For example, if a researcher first changes one gene and then adds a drug, the second experiment can take into account the consequences of the first. This is a significant departure from traditional prediction models, where each prediction is treated as an independent question. As demonstrated by GenBio using imatinib, a drug used to treat certain types of leukemia, the model was able to reproduce the known mechanism of action at multiple levels of cellular biology, as reported in Nature Aging, July 2026.

🔗 Read original →

Gene editing boost


The University of Wisconsin-Madison team published a genetic screen on August 13, in which they sequentially turned off 19,114 human genes and observed how it changed the work of the DNA editor, delivered by lipid nanoparticles. Six genes passed the re-test, and the shutdown of GJB2 and BET1L enhanced editing in several cellular models.

The DNA editor Cas9 was delivered in a lipid nanoparticle - a fatty shell with protein and guide RNA. After entering the cell, the cargo must be released from the intracellular bubble and reach the nucleus, where the DNA is located. In this screen, one gene was turned off in each cell, and sequencing - reading the DNA sequence - showed which gene was turned off and whether the editor was able to change the desired site.

The authors separately checked 26 candidates, and six had a repeated effect. The shutdown of GJB2 and BET1L increased the efficiency of editors that change individual "letters" of DNA without cutting both strands. In cells with a model mutation KCNJ13, the suppression of GJB2 gave 19.3% corrections - 6.7 times more than in control cells.

The team then checked at what point in the path the difference arises, as described in the Nature Aging, July 2026 journal. When Cas9 was introduced by electroporation - an electric pulse through the cell membrane - the advantage of cells with turned-off genes disappeared in most candidate lines.

🔗 Read original →

Bone Tissue Restored


Researchers have partially restored the mineral and mechanical signals of aging bone tissue using OsteoVes, artificial particles designed to restore mineral deposition and mechanical signals in aging bone tissue. In experiments with cells from elderly donors, old mice, and three macaques, they shifted measurable indicators towards bone formation.


The study, published in Cell Reports Medicine on August 18, found that mesenchymal stromal cells in bone marrow can become either bone-building cells or fat cells, influenced by the extracellular matrix, a environment of proteins and minerals surrounding the cell. With age, the matrix becomes less effective at depositing minerals and transmitting mechanical signals to cells.


The authors of the new study had previously altered the mechanical properties of the environment in bone injuries using a hydrogel that mimicked a blood clot, helping cells to activate their bone formation program. Now, they have tested whether temporarily replacing the functions of the matrix can direct bone marrow cells towards bone formation, even in aging tissue. The OsteoVes particles, which mimic matrix vesicles of bone tissue, contain alkaline phosphatase that breaks down pyrophosphate, which hinders mineralization, and hydroxyapatite nanoparticles, which provide a starting point for mineral deposition.


The authors compared the complete construct to its individual components and found that OsteoVes enhanced the formation of mineralized matrix and the activity of genes associated with bone formation in old human stromal cells. Variants without the enzyme or hydroxyapatite and empty membrane vesicles were less effective. When the researchers blocked PIEZO1, a protein channel that helps cells respond to mechanical stimuli, the effect was also weakened. The authors then tested whether the bone tissue of old animals could be changed, and found that two intravenous doses of OsteoVes administered one week apart increased the maximum load that the femur could withstand by approximately 1.4 times in 22-month-old mice, and improved the bending strength by approximately 95% compared to a saline control.

🔗 Read original →

Brain Cell Aging


Researchers studied how different brain cell types interact and transmit signs of aging. On August 15, a study was published in Aging Cell, where scientists transferred media from five human brain cell types to each other and measured which cells developed signs of aging. A 15-day experiment showed that astrocytes and microglia more often triggered such responses in other cells.


The study focused on cellular aging, or senescence, a state where a cell stops dividing and changes its function after stress. It releases a set of proteins and molecules, known as SASP, into the surrounding environment, which can alter the state of neighboring cells. The authors worked with five human immortalized cell lines, including astrocytes, vascular lining cells, microglia, oligodendrocytes, and neuron-like cells.


The cell cultures were treated with BrdU for seven days to induce signs of aging. Then, the media from each cell type was transferred to other cells. The media from treated astrocytes and microglia increased the proportion of cells with SA-β-gal, a senescence marker, in astrocytes and vascular lining cells. Microglia responded to media from several other cell types, and the authors further checked other senescence markers, such as DNA damage and mitochondrial function.

🔗 Read original →

AIntibody Test Results


The AIntibody blind test involved 511 antibodies submitted by 29 organizations for three tasks, with independent laboratories synthesizing and testing them under the same conditions. An antibody is a protein that recognizes and binds to a specific target, requiring a strong bond, sufficient production, stable form, and selectivity to its target.


The competition measured both the rare best result and the fraction of variants that a laboratory could work with further, using the logic of blind tests from CASP. The AIntibody competition continued from 2024, where participants submitted antibody sequences in advance, with all variants first tested using surface plasmon resonance to measure binding to the target, and the strongest further measured using KinExA.


In the task of improving an already known antibody, a variant from company Aureka bound to the target as strongly as the best laboratory variant, with 94.7 versus 113 pM by KinExA, and their 95% uncertainty intervals overlapped. This was the result of one team in the task where participants were given data from the first stage of laboratory selection, with the target being the RBD of SARS-CoV-2. The results were published in Nature Biotechnology on August 19.

🔗 Read original →

Ben Goertzel's Omega Point


Ben Goertzel published an essay "Arrow of Time, Part 2" on August 15, where he links subjective time to the recording of new significant differences and suggests leaving a history of changes for future mind versions. As the mind rewrites models, expands memory, and learns to reason anew, its future version stores and processes experience differently. The connection between versions is maintained by whether a later version can translate previous ways of representing experience into its new representations.


The analysis of digital personality continuity separates working memory, holding current thought, from episodic memory, which links a person to the past. Goertzel sets a related technical challenge for the self-modifying mind: a later version needs an archive that it can read after changing its own ways of thinking. In Goertzel's model, subjective time grows with the record of significant differences: they change the world model and help choose actions later. When the system masters unfamiliar situations, it must preserve the differences on which choice depends.


Goertzel comes to the "Omega Point": the mind retains a common direction - values, ability to correct itself, and coordinate its parts - as the history of experience continues to grow. In this model, stability lies in the direction, while the internal state changes with the growing history. Rapid self-modification increases the requirement for such continuity. Goertzel formulates it as: "The faster the stream of differences, the smaller the average self-translation error should become." As an engineering step, he suggests dividing memory into two parts: working memory that can be rewritten and a replenished journal where the system's conclusions are recorded. This journal retains both corrections and deletions; a later version can compare its transformations with how early representations were organized. Goertzel's philosophical question about personality continuity takes on an engineering form: a future version of the mind must be able to read its own history and verify the connection with early representations, as discussed in Nature Aging, July 2026.

🔗 Read original →

Stroke Recovery Boost

The IpsiHand home system, which reads brain electrical signals, improved hand movement after stroke more than exercises. On August 13, a randomized BCI-REHAB study was published, with a primary analysis of 62 people with chronic hand movement impairment after stroke. It compared the IpsiHand home neurointerface with exercises.


The system converts an attempt to move the affected hand into finger movement; the control group trained their hand on the same schedule. For some people after stroke, attempting to move their hand no longer leads to wrist movement. IpsiHand builds rehabilitation around this attempt: EEG - recording electrical brain activity from the surface of the head - captures a signal pattern in the unaffected hemisphere associated with imagined movement of the affected hand.


When the system recognizes it, a device attached to the wrist opens and closes the fingers in a three-finger grip. Early research showed that such a signal can be used to control wrist movement. The BCI-REHAB study checked if this connection improves rehabilitation more than the same amount of home exercises. Before distribution, each participant's EEG signal was checked to see if it was sufficient to control the device. The primary analysis included 37 people with IpsiHand and 25 with a hand, wrist, elbow, and shoulder movement program, including household tasks: opening a drawer or lifting a cup.

🔗 Read original →

Aging Skin Study


Researchers found that in the aging epidermis of mice, the proteins BMAL1 and YAP together activate inflammatory genes. A recent study published in Nature Aging, August 2026 investigated the outer layer of mouse skin, tracing how BMAL1, a biological clock protein, and YAP, a protein responding to tissue mechanical properties, alter the function of inflammation genes.


The epidermal cells of old mice receive two changing signals: one from the tissue beneath them and another from immune cells. The basement membrane, a thin layer between the epidermis and the deeper dermis, resists deformation more strongly, while the dermis accumulates cells releasing IL-17, a molecule signaling inflammation.


The authors compared adult and old epidermis at six points in the daily cycle, finding that among 118 inflammatory genes more active in old skin, only four changed rhythmically. This suggests that BMAL1 is involved in a sustained age-related reorganization of gene function, not just daily fluctuations.

🔗 Read original →

US Seeks Bio Risk Protection


The US White House is seeking protection from biological risks associated with AI after cutting a high-profile team. By the end of the Joe Biden administration, the White House had up to 30 biodefense specialists. After cuts and reorganizations, former officials said there were periods when no dedicated staff member was working on the issue. Protection from biological risks of AI involves several actions, including assessing risk throughout the workflow of a trained biologist.


The risk assessment path shows that a model can help design a DNA sequence, a synthetic DNA supplier can check an order, and a laboratory can provide access to equipment and biological samples. Government policy connects these points with rules and agency work. One of these points is the ordering of synthetic DNA. The 2024 framework tied federal funding to sequence and buyer screening: laboratories must purchase DNA, other nucleic acids, and desktop devices for their synthesis from suppliers that comply with these requirements.


A White House directive on May 5, 2025, gave the White House Office of Science and Technology Policy 90 days to review or replace the framework. On July 28, the US Department of Health and Human Services announced a new national policy for oversight of high-risk life sciences research, which prohibits federal funding for certain work that intentionally enhances dangerous properties of pathogens and introduces independent review of certain high-risk research, as reported in The Washington Post.

🔗 Read original →

Bone Repair Falters

After repeated injury in mice, less new bone formed, although the bone marrow appeared recovered. In an article published on August 19 in Nature Communications, scientists investigated whether bone marrow cells could re-engage in bone repair after a previous injury. After a second injury, their descendants less often became osteoblasts, and less new bone formed.

The bone marrow's stromal cells support the environment within the bone marrow. After injury, some of these cells can become osteoblasts - cells that build bone. To track this change, the authors genetically labeled cells in mice and compared one and two operations that triggered bone marrow repair. After the second operation, micro-CT scans showed that less new trabecular bone formed.

The labeled cells less often transformed into osteoblasts, and their descendants more often became adipocytes of the bone marrow. In a separate model of repeated fractures, the same pattern emerged: less new bone and osteoblasts, more adipocyte descendants. Initially, the interval between operations was about four weeks. By the next injury, the bone marrow under the microscope already appeared comparable to the undamaged one.

🔗 Read original →

Brain Blood Flow

The protein cMAF helps immune cells near brain artery walls maintain vessel response to CO2 and cerebrospinal fluid movement. On August 14, authors described this mechanism, finding that perivascular macrophages depend on cMAF to function properly.


When cMAF was removed in mice, cerebrospinal fluid movement and vessel response to excess CO2 were disrupted. Researchers had previously shown in 2022 that perivascular macrophages participate in cerebrospinal fluid movement, and now sought to understand the genetic program supporting these cells' function.


Authors compared gene activity in different brain macrophages and identified cMAF. They then removed the Maf gene, which codes for cMAF, in mice, finding that macrophages around arteries lost a characteristic set of active genes, and fluorescent marker flow decreased along the middle cerebral artery.


The authors investigated how this relates to vessel function, administering a mixture with 10% CO2 to mice. In control animals, arteries dilated and brain blood flow increased, but this response disappeared after cMAF removal. The protein IGF1 was found to be a key signal transmitted from macrophages to the vessel wall, with IGF1R as its receptor.


In human brain data, MAF was found to be the most active regulator in perivascular macrophages, with its activity and IGF1 levels increasing with amyloid deposits in APOE3 variant carriers. A genetic variant near MAF was associated with higher MAF activity and lower Alzheimer's disease risk, as described in Nature Aging, July 2026.

🔗 Read original →

Brain Organoids Live

Brain organoids, once limited to a few months of life, can now survive for years and age like real brains. These tiny tissue pieces, created from stem cells, mimic the earliest stages of human brain development. Typically, such organoids are grown for 2-3 months, but a new study has kept them alive for up to seven years. This allowed researchers to observe how brain cells change over long periods: which cell types emerge, how their function changes, and how gene activity shifts. Most interestingly, they began to show signs of "aging" as metabolic groups accumulated in their DNA.


The lab-grown tissue did not just exist for a long time; it underwent similar maturation and aging processes as a real brain. Researchers observed a diversity of cells, the formation of more complex structures, and changes that usually occur in the human brain over many years. This is particularly useful, given that some diseases (Parkinson's, schizophrenia, Alzheimer's) only manifest with age. Previously, it was impossible to study these diseases using organoids, as the model did not survive long enough to reach the necessary stage. Now, scientists have a tool to observe long-term changes in neural networks and cellular processes, as reported in Nature, July 2026.

🔗 Read original →

New Theory of Aging


Researchers Michael Levin and co-authors proposed a third theory of aging, where cells lose their common goal to maintain tissue shape. On August 18, Leo Pió-López, Navnit Javanda, and Michael Levin published a preprint review of aging theories. The authors group these theories by their presumed primary cause: accumulation of damage, late consequences of evolutionary programs, and loss of coordinated cell purpose in tissue.


The authors' own theoretical model describes how cells maintain the overall structure of tissue. By "purpose," the authors mean the work of feedback: cells compare the current state of tissue with its target structure and reduce the discrepancy. During development, this process creates the body's form. According to the authors' model, after development is complete, cells may maintain their local functions but poorly coordinate repair, growth, and cell replacement with the organ's form.


One possible carrier of such coordination, the authors consider, is bioelectric patterns - the distribution of electrical potentials in tissue. The review also mentions chemical signals and mechanical properties of tissue. If cells poorly maintain or read the common scheme of signals, the tissue, according to the authors' hypothesis, deviates from the necessary structure and function, as seen in Nature Aging, July 2026.

🔗 Read original →

Merck and Moderna Report Success


Merck and Moderna reported on August 19 the results of the INTerpath-001 phase III study with 1,137 participants. After complete removal of high-risk melanoma, all participants received pembrolizumab: one group was also given a personally tailored intismeran, while the other received a placebo.


The companies reported that the combination achieved two study goals: time without recurrence and time without distant metastases. After melanoma removal, the risk of its return remains. Pembrolizumab is an immunotherapy that blocks the PD-1 protein, which reduces the activity of T-cells that can attack tumors. Intismeran gives these cells specific targets.


According to oncologist Lennard Lee, as quoted in the Science Media Centre, the combination of the two drugs works by "one helping the immune system understand what to look for, and the other taking the brakes off the immune response". For intismeran, a tumor sample from a specific patient is taken, and up to 34 neoantigens - fragments of proteins that distinguish cancer cells from healthy ones - are selected. Their sequences are recorded in mRNA: after injection, the patient's cells produce these fragments and show them to T-cells.

🔗 Read original →

Longevity Interventions


Яцек Хоффман proposes selecting combinations of anti-aging interventions based on the current state of the organism. On August 19, Яцек Хоффман published an essay with his author's hypothesis: to maintain health throughout a long life, it is necessary to evaluate several processes at once and select their combination based on the state of the organism. The starting point for Хоффман was a study on the heart of the Greenland shark. The authors studied the tissues of ten sharks aged approximately 100-155 years and found fibrosis, lipofuscin, and signs of oxidative stress.

Before capture, the animals were found, chased, and caught with bait; the authors consider this indirect evidence of preserved physiological function. Хоффман takes the discrepancy between tissue damage and active behavior of the sharks as a reason to question this in humans. In his hypothesis, the organism must maintain several processes at once, and enhancing one changes the conditions for the others.

Active removal of damaged cells helps to restrain tumors, but increases the tissue's need for restoration. Stem cells replenish lost cells; the more they divide, the more the tissue is renewed and the more opportunities there are for changes in individual cells. The immune system recognizes infections and anomalous cells, and its prolonged activation damages tissues. One intervention changes the work of other systems.

Therefore, Хоффман proposes choosing an intervention based on age, specific tissue, accumulated damage, and resource reserve. His sequence of actions looks like this: "Observation → reconstruction of the current state → causal model → selection of intervention → action → repeated measurement → model update". Хоффман proposes testing this hypothesis by comparing models, such as those described in Nature Aging, July 2026.

🔗 Read original →

Tomorrow Bio Report


Tomorrow.bio released a video and table on August 18 about five cryonics providers, comparing their legal structure, standby procedures, storage, and patient care funding. A cryonics contract links the first hours after official death declaration with decades-long storage.


In a breakdown by Max More, cryocenters were evaluated based on their performance in the first hours and their ability to store patients for decades. Before placement in liquid nitrogen, a standby team stabilizes the patient, administers cryoprotectants, and arranges transportation. Then, someone must maintain the storage facility and manage the patient care funds.


Tomorrow.bio released a video about the five providers on August 18 and published a table on its website with their legal forms, storage, standby procedures, and financing. The table was compiled by Tomorrow.bio itself, one of the comparison participants; in the video, the company asks for error reports in the data. Tomorrow.bio distributes its functions among three organizations: it keeps medical teams on standby, performs the procedure, and handles contracts.


The European Biostasis Foundation, a separate Swiss non-profit foundation, owns the storage facility and is responsible for the care within it. Co-founder Emil Kendziorra associates this scheme with different terms of work: the storage facility needs decades-long stability, while the operational company must change technologies and procedures. A contract with a provider can be read through four specific questions: who will attend to the patient, where they will be stored, who manages the patient care funds, and what happens if one of the organizations ceases to operate.

🔗 Read original →